drugset / Trial / NCT07706088

Effect of Tirzepatide on Diabetic Peripheral Sensorimotor Neuropathy

NCT07706088

RandomizedParallel-groupOpen-labelTreatment

Summary

Tirzepatide is a dual agonist of GLP-1 Receptor and the GIP receptor, producing substantial improvement in glycaemic control, weight reduction and insulin sensitivity. Beyond its metabolic effects, incretin signalling has demonstrated neuroprotective and neurotropic properties, including activation of intracellular pathways that enhance neuronal survival and regeneration. Using tirzapatide for diabetic sensorimotor peripheral neuropathy and assessing with CCM / NCS and BDNF will represent three complementary aspects of nerve regeneration: metabolic control, structural nerve repair and neurotrophic signalling.

Timeline

Start
2026-07
Primary completion
2028-07-01
Completion
2028-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tirzepatide Peptide 7.5 mg